ZNTL (Zentalis Pharmaceuticals) Valuation Rank


ZNTL Zentalis Pharmaceuticals Inc ZNTL
30 GF Score
Price $4.72
! 3 Warning Signs
View Full Analysis

What is Zentalis Pharmaceuticals Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Zentalis Pharmaceuticals Valuation Rank Related Terms

ZNTL
30GF Score
Zentalis Pharmaceuticals Inc ZNTL
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zentalis Pharmaceuticals Business Description

Address 10275 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
30GF Score

Get the complete analysis for ZNTL

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.72
Price